BNI Asset Management Collaborates with BNI Marketers to Visit Kalbe Farma Issuer

Jakarta – BNI Asset Management (BNI AM) in collaboration with APERD Bank BNI held a Company Visit to Kalbe Farma (KLBF) at the Kalbe Business Innovation Center, East Jakarta on February 17, 2025. This Company Visit program aims to introduce Bank BNI mutual fund marketers to one of the issuers that is a constituent of the BNI-AM index mutual fund in order to get an overview of the company's operations and innovations achieved.
The Company Visit group was led by the President Director of BNI AM, Mr. Ari Adil who was present with 30 participants. The BNI AM group was well received by the Kalbe Farma Management, namely: dr. Sandy Qlintang M. Biomed as President Director of PT Bifarma Adiluhung and Syeren Amanda - Head of Investor Relations Kalbe Farma.

The agenda of the event was a speech and a brief presentation about Kalbe Farma's business (company profile) delivered by dr. Sandy Qlintang and continued by Mrs. Yeren Amanda as Head of Investor Relations Kalbe Farma. After the Company's presentation, it was continued with a sharing session and question and answer session regarding the Stem Cell development program and its benefits for human health.

In his speech, Ari Adil explained, "This activity is a means of information and enrichment of knowledge for APERD Bank BNI, especially marketers, to understand the ins and outs of the issuer's business that was selected as a constituent of the BNI-AM Index mutual fund". This activity is one of our supports to APERD in the form of information and education and is part of the loyalty program for APERD, thus Ari Adil closed his speech. For information, KLBF shares are constituents of the BNI-AM IDX30 Mutual Fund (BNI30), BNI-AM Sri-Kehati class R1, BNI-AM Index Growth30 (BNI30G) class R1, BNI-AM IDX Sharia Growth class R1, ETF Selection Index, and BNI-AM Nusatara ETF MSCI Indonesia (XBNI).

This Company Visit Program is BNI AM's first Company Visit program in 2025. Kalbe Company was chosen because of its good reputation and solid financial performance. Various information and knowledge were absorbed in this office tour, especially about business growth and product innovation, especially stem cell development. At the end of the event, an office tour was conducted to the laboratory where stem cells and secretomes are developed, which is currently one of Kalbe Farma's very promising new businesses.